Robbins LLP Encourages ADMA Shareholders to Join Class Action Lawsuit for Financial Redress
On June 23, 2026, Robbins LLP, a prominent law firm specializing in shareholder rights, announced the initiation of a class action lawsuit involving ADMA Biologics, Inc. (NASDAQ: ADMA). This action is intended for investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, and subsequently faced significant losses. ADMA Biologics is known for its development and manufacturing of specialty plasma-derived biologics, aimed at treating immune deficiencies and infectious diseases globally.
The class action stems from allegations that the company misrepresented key operational aspects to its shareholders, leading to substantial misinformation. According to the formal complaint, ADMA made a series of false and misleading statements and withheld crucial information regarding its business practices. Specific allegations include undisclosed related party transactions, misleading revenue representations through channel stuffing, inadequate internal control measures, and ultimately misleading statements regarding the company's operations and future prospects.
The tide turned for ADMA on March 24, 2026, when Culper Research released a damaging report titled 'ADMA Biologics Inc (ADMA) Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported.' This report highlighted significant discrepancies in ADMA’s reported growth figures, attributing them to channel stuffing practices and an undisclosed distribution relationship with Genesis BioPharma Services, which allegedly operated from ADMA's headquarters. The fallout from this revelation was immediate; on March 24 alone, ADMA's stock plummeted by $2.26 per share, a staggering 16.6% decrease, continuing its decline to an additional $1.70, or 15.0%, the following day.
For shareholders eager to act, Robbins LLP encourages those potentially eligible to participate in the class action. Shareholders can apply to serve as lead plaintiffs by filing necessary documents with the court by August 10, 2026. The lead plaintiff's role is significant, acting on behalf of the class members and directing the litigation. However, it’s crucial to note that participation in the case is not necessary to recover any damages; shareholders may choose to remain absent from the proceedings and still be eligible for compensation.
All legal representation in this case operates on a contingency fee basis, meaning shareholders incur no costs unless the case is successful. Robbins LLP has established itself as a leader in empowering shareholders, guiding them toward recovering losses, enhancing corporate governance measures, and ensuring accountability among company executives.
For those interested in staying informed about the lawsuit's progress or if they wish to receive updates on corporate misconduct, Roberts LLP invites individuals to enroll in their Stock Watch service. Such measures provide essential alerts when significant developments occur, ensuring that shareholders remain in the loop regarding their investments.
In summary, the class action lawsuit against ADMA Biologics represents a pivotal opportunity for investors to seek justice and compensation for their losses. As allegations of misleading statements and inadequate disclosures surface, shareholders are urged to consider their options and take action promptly. With the expertise of Robbins LLP, affected shareholders can navigate this challenging landscape in pursuit of their rights in this class action lawsuit.
For further inquiries, interested parties can reach out to Robbins LLP directly, either through their online form, email attorney Aaron Dumas, Jr., or contact them at (800) 350-6003.
The class action stems from allegations that the company misrepresented key operational aspects to its shareholders, leading to substantial misinformation. According to the formal complaint, ADMA made a series of false and misleading statements and withheld crucial information regarding its business practices. Specific allegations include undisclosed related party transactions, misleading revenue representations through channel stuffing, inadequate internal control measures, and ultimately misleading statements regarding the company's operations and future prospects.
The tide turned for ADMA on March 24, 2026, when Culper Research released a damaging report titled 'ADMA Biologics Inc (ADMA) Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported.' This report highlighted significant discrepancies in ADMA’s reported growth figures, attributing them to channel stuffing practices and an undisclosed distribution relationship with Genesis BioPharma Services, which allegedly operated from ADMA's headquarters. The fallout from this revelation was immediate; on March 24 alone, ADMA's stock plummeted by $2.26 per share, a staggering 16.6% decrease, continuing its decline to an additional $1.70, or 15.0%, the following day.
For shareholders eager to act, Robbins LLP encourages those potentially eligible to participate in the class action. Shareholders can apply to serve as lead plaintiffs by filing necessary documents with the court by August 10, 2026. The lead plaintiff's role is significant, acting on behalf of the class members and directing the litigation. However, it’s crucial to note that participation in the case is not necessary to recover any damages; shareholders may choose to remain absent from the proceedings and still be eligible for compensation.
All legal representation in this case operates on a contingency fee basis, meaning shareholders incur no costs unless the case is successful. Robbins LLP has established itself as a leader in empowering shareholders, guiding them toward recovering losses, enhancing corporate governance measures, and ensuring accountability among company executives.
For those interested in staying informed about the lawsuit's progress or if they wish to receive updates on corporate misconduct, Roberts LLP invites individuals to enroll in their Stock Watch service. Such measures provide essential alerts when significant developments occur, ensuring that shareholders remain in the loop regarding their investments.
In summary, the class action lawsuit against ADMA Biologics represents a pivotal opportunity for investors to seek justice and compensation for their losses. As allegations of misleading statements and inadequate disclosures surface, shareholders are urged to consider their options and take action promptly. With the expertise of Robbins LLP, affected shareholders can navigate this challenging landscape in pursuit of their rights in this class action lawsuit.
For further inquiries, interested parties can reach out to Robbins LLP directly, either through their online form, email attorney Aaron Dumas, Jr., or contact them at (800) 350-6003.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.